Capital Advisors Ltd’s GT Biopharma GTBP Stock Holding History

Capital Advisors Ltd’s Portfolio GTBP Stock Details GTBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1	Closed	–	–	1331
2022 Q2	$0	Hold	1	–	–	﹤0.01%	1127
2022 Q1	$0	Buy	+1	New	+$88	﹤0.01%	1028

Other funds holding GTBP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

AWS

Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CLOS

Compagnie Lombard Odier SCmA 1204 Geneva, Switzerland $8.13B AUM 26.03% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Capital Advisors Ltd's GTBP Position: Q3 2022 in Review

Capital Advisors Ltd sold out of GT Biopharma (GTBP) in Q3 2022, closing a stake of 1 share.

Capital Advisors Ltd first reported a position in GTBP in Q1 2022 and held it in 2 quarters. The position peaked at $0 in Q2 2022. 34 funds tracked by Wall St. Rank hold GTBP as of Q3 2022.

Capital Advisors Ltd reported no remaining GT Biopharma position as of Q3 2022 after selling out during the quarter.
Capital Advisors Ltd sold 1 GT Biopharma share in Q3 2022.
Capital Advisors Ltd first reported a position in GT Biopharma in Q1 2022 and held it in 2 quarters.
Capital Advisors Ltd's GT Biopharma position peaked at $0 in Q2 2022.
34 funds tracked by Wall St. Rank held GT Biopharma as of Q3 2022.

Based on Capital Advisors Ltd's 13F filing for Q3 2022, filed 9 Nov 2022.